• FDA asks for additional data to approve Evenity in US pharmaceutical-technology
    July 19, 2017
    Pharmaceutical companies Amgen and UCB have received a Complete Response Letter from the US Food and Drug Administration (FDA) for Evenity, a treatment for postmenopausal women with osteoporosis.
PharmaSources Customer Service